Greetings, fellow investors! Welcome back to ShareTreck. I'm Raj, today I am going to share my impression of the Crispr landscape and how other companies are covering ground with new disease indications. The emerging innovations and how CRISPR therapeutics needs to run fast to maintain its lead post Casgevy.

Well this is my personal opinion, not financial advice.

JOIN THE CHANNEL AS A MEMBER:

Please check out the membership offering and join me in the exciting new chapter for ShareTreck, Thanks for your support so far and looking forward to much more. Use the link below to join or click on the Join button on the bottom left of your screen or copy the link below to your browser address bar and press enter.

[ Ссылка ]

Please subscribe: [ Ссылка ]

The videos in this channel should not be construed as financial advice. Always make sure to do your own due diligence and research.
Please do not trade or invest based on this video. Information provided in this video is not investment advice and is for entertainment purposes only.
In case of coverage of pharma companies, disease and therapy details are derived from news articles and publications by companies or research organizations. I am not a doctor but am only facilitating dissemination of published information.

свернуть